Please login to the form below
inflammatory diseases
This page shows the latest inflammatory diseases news and features for those working in and with pharma, biotech and healthcare.
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
The five-year deal includes Sitryx’ two lead projects, although there’s little information available yet on the diseases targeted by those programmes as they are still in the discovery phase. ... The partnership complements Lilly’s existing focus
Latest news
-
Bayer signs €250m pact with India’s Curadev for STING drugs
Research will focus on auto-immune and inflammatory diseases. The immune checkpoint STING has seen some popularity as a target for cancer drug development, but Bayer and India’s Curadev have ... started working on STING drugs with potential in
-
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
The two companies have been collaborating since December 2018 on the development of BPN14770, a phosphodiesterase 4D inhibitor that is also in testing for other diseases linked to cognition and memory ... PDE 4 inhibitors are already used to treat
-
Takeda buys coeliac disease partner PvP Biologics after phase 1 win
Takeda paid up to $100 million in funding to deploy GammaDelta’s T cell platform to find new therapies for cancer and autoimmune/inflammatory diseases.
-
Sanofi says it will spin out active ingredient business by 2022
investment in immunological/inflammatory diseases, rare blood disorders, cancer and vaccines as well as digital healthcare.
-
Tocagen merges with Forte Biosciences after brain cancer fail
The newly merged company will operate under Forte’s name and will focus on the development of Forte’s lead asset FB-401, a biotherapeutic for the treatment of inflammatory skin ... We are excited about the opportunities created by this merger, as it
More from news
Approximately 4 fully matching, plus 126 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
In the meantime, Sanofi is stepping up its focus in other areas like immunological and inflammatory diseases, rare blood disorders and vaccines, as well as cancer – an area it had been ... Meanwhile, Galapagos looks set to continue adding to its
-
Innovation in merger control and the impact on the pharmaceutical sector
Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s disease, while Pfizer was in an advanced stage of developing
-
‘How is your day?’
Physicians need to be more aware of rare diseases that may hide behind recurring issues that some patients have. ... These are: Primary Immunodeficiency Diseases (PID – causes severe infections); Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
-
The tipping point
In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.
-
Case study: From Clinical Trials to Real-World Evidence
on Product X’s real-world experience and heritage within dermatology and rheumatology, since these diseases share a common inflammatory mediator targeted by Product X.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences
He has 30 years’ experience in research and development specifically in gastrointestinal disorders, inflammatory diseases and cancers, and previously co-founded Synergy Pharmaceuticals and served as its chief scientific officer.
-
Kymab appoints its first chief medical officer
She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
-
Dr Li Zhou joins TxCell as cell engineering VP
Dr Zhou will lead the team's discovery and engineering activities on Chimeric Antigen Receptor in Treg cells ( CAR-Treg) for immunotherapy of severe chronic autoimmune and inflammatory diseases and organ
-
Vedanta Biosciences appoints two new heads
Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Infographic: Spondyloarthritis
Overview of spondyloarthritis patient profiles and treatment pathways. Spondyloarthritis is the name for a family of arthritis causing inflammatory rheumatic diseases; including axial spondyloarthritis, psoriatic arthritis and akylosing spondylitis,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
